Jury Hits Takeda With $885 Million Antitrust Verdict

Takeda Pharmaceutical Company Limited (NYSE:TAK) on Monday said a Massachusetts jury awarded nearly $885 million in damages against the company in litigation tied to its constipation drug Amitiza (lubiprostone), with portions of the award subject to automatic trebling...